Ask Warren

Cell Bio Human Tech

318160 · KOSDAQ · ₩318160 · 셀바이오휴먼텍

₩6,100▼ ₩150 (2.40%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩19B₩13B₩14B₩15B₩14B₩8.3B₩8.3B₩7.1B
Cost of sales₩13B₩8.9B₩9.7B₩8.8B₩9B₩4.8B₩5.3B₩4.7B
Gross profit₩6.2B₩3.8B₩4.6B₩5.7B₩5B₩3.5B₩3B₩2.4B
Operating income₩3.5B₩1.5B₩1.2B₩3.6B₩3B₩1.5B₩1.3B₩1.2B
Net income₩1.1B₩1.8B₩5.2B₩1.9B₩243M₩1.4B₩3.4B₩137M
Net income to shareholders₩2.9B₩1.9B₩2.2B₩3.5B₩1.6B₩1.4B₩2B₩955M

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩92B₩90B₩88B₩64B₩54B₩55B₩53B₩53B
Current assets₩42B₩46B₩44B₩31B₩26B₩26B₩24B₩26B
Cash and equivalents₩11B₩19B₩16B₩11B₩7.2B₩3.3B₩3.1B₩2.5B
Total liabilities₩28B₩29B₩29B₩12B₩7.4B₩8.1B₩6.5B₩7.7B
Current liabilities₩15B₩19B₩19B₩8.7B₩7.2B₩8B₩6.3B₩7.5B
Borrowings₩20B₩21B₩20B₩7B₩3.5B₩3.7B₩3.7B₩5.1B
Total equity₩64B₩61B₩59B₩52B₩47B₩47B₩46B₩45B
Shareholders' equity₩61B₩59B₩57B₩52B₩47B₩47B₩46B₩45B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩1B₩2.2B−₩390M₩3.9B−₩2.7B₩688M₩2.3B₩1.1B
Capital spending₩7.5B₩1.4B₩269M₩4B₩254M₩2.1B₩1.5B₩387M
Free cash flow−₩6.5B₩847M−₩659M−₩126M−₩3B−₩1.4B₩827M₩754M

Consolidated where available. Amounts in won.

Also known as: Cell Bio Human Tech / 셀바이오휴먼텍 / 318160 / KRX:318160

Source: KRX statistical information